Find → Understand → Decide
Temsirolimus
Discovery priority: MEDIUM · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): financing failure; inadequate public evidence
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: CORPORATE/FINANCIAL
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2025-09-25 · trial:NCT01326468
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
funding
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: financing failure · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "85cc2c6b880b602903dea67dd489d377febc51f48243eb52a35d3dc6fc26c910",
"metadata": {
"complete": false,
"content_hash": "12dba2f64d20d48c47f4c2e04478803287ca92675724e452ceace13362b9457a",
"failed": false,
"last_checked": 1790026982.205955,
"last_success": 1790026982.205955,
"live_verified": true,
"scope": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "12dba2f64d20d48c47f4c2e04478803287ca92675724e452ceace13362b9457a",
"raw_path": "research/obz7_sources/12dba2f64d20d48c47f4c2e04478803287ca92675724e452ceace13362b9457a.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT01326468"
}2026-05-15 · trial:NCT01552434
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
\< 75 % participation
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "78a69eb3234315ccbab04f6dada76e62fef2202507c742358ffe7abaa16f72bb",
"metadata": {
"complete": false,
"content_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"failed": false,
"last_checked": 1790026980.1182604,
"last_success": 1790026980.1182604,
"live_verified": true,
"scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"raw_path": "research/obz7_sources/0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT01552434"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.118260+00:00
clinicaltrials · STALE · AREA[OverallStatus]WITHDRAWN AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:02.205955+00:00
Registry observations (2)
NCT01552434 · TERMINATED · PHASE1 · Advanced Malignant Neoplasm; Castleman Disease; Digestive System Carcinoma; Erdheim-Chester Disease; Lip and Oral Cavity Carcinoma; Lymphangioleiomyomatosis; Malignant Endocrine Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Male Reproductive System Neoplasm; Malignant Neoplasm; Malignant Respiratory Tract Neoplasm; Malignant Thoracic Neoplasm; Malignant Urinary System Neoplasm; Mesothelial Neoplasm; Metastatic Malignant Neoplasm; Metastatic Urothelial Carcinoma; Neurofibromatosis Type 2; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Digestive System Carcinoma; Recurrent Female Reproductive System Carcinoma; Recurrent Male Reproductive System Carcinoma; Recurrent Malignant Neoplasm; Recurrent Pharyngeal Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Neoplasm; Soft Tissue Neoplasm; Stage III Breast Cancer AJCC v7; Stage III Pharyngeal Cancer; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Pharyngeal Cancer; Stage IVA Pharyngeal Cancer; Stage IVB Pharyngeal Cancer; Stage IVC Pharyngeal Cancer; Thyroid Gland Neoplasm · Trial sponsor M.D. Anderson Cancer Center
Reported aliases: CCI-779; CCI-779 Rapamycin Analog; Cell Cycle Inhibitor 779; Rapamycin Analog; Rapamycin Analog CCI-779; Torisel. Identity, treatment role and exposure require review.
NCT01326468 · WITHDRAWN · NA · Head and Neck Cancer · Trial sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Reported aliases: Torisel; CCI-779. Identity, treatment role and exposure require review.